Previous 10 | Next 10 |
Olema Pharmaceuticals has filed to raise $100 million in an IPO, although the final figure may differ. The firm is advancing its OP-1250 drug to treat various women's cancers as a monotherapy and in combination with other drugs. OLMA has a collaboration deal with Novartis, which i...
Completed e nrollment in 3 p ivotal c linical t rials; multiple data read outs in Q4 2021 Released meaningful abaloparatide histomorphometry data at recent ASBMR meeting Completed two business development transact...
WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the resul...
WALTHAM, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy and Transactions (CST) G...
Radius Health (RDUS) down 4% in premarket, has divested its second oncology pipeline asset, RAD140 to Ellipses Pharma, completing Radius’s divestment of its oncology assets.Under the agreement, Ellipses Pharma will take over the clinical development and commercialization of t...
Business development step enables molecule to move forward Program progression will be at no financial risk to Radius Reinforces Radius ’ focus on execution of core business WALTHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc...
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radiusȁ...
Radius Health (RDUS) announces that chief financial officer Jose (Pepe) Carmona will be stepping down with immediate effect."Pepe joined Radius one month after the FDA approval of TYMLOS® in 2017 and he has been instrumental in helping Radius advance from a development com...
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Mee...
Innovative transdermal technology enables delivery of abaloparatide molecule – a peptide - across the skin Trial success followed by regulatory approval would provide a completely unique drug administration option for postmenopausal women with osteoporosis. wearABLe progress ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 54.4% to $0.4264 on volume of 158,036,142 shares Versus Systems Inc. (VS) rose 73.5% to $2.29 on volume of 40,036,424 shares Tesla Inc. (TSLA) rose 5.3% to $220.97 on volume of 32,375,487 shar...
Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the third quarter of fiscal 2024 ended May 31, 2024. ...